Obesity and overweight
Conditions
Interventions
Observation group:NA
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects who have completed the safety follow-up of the randomized, double-blind, placebo-controlled Phase IIa clinical study (YN011-W201) (light) on the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of multiple subcutaneous administrations of Efsubaglutide Alfa Injection in overweight and obese subjects with poor weight control after dietary and exercise interventions; 2.Those who have not participated in other weight loss clinical trials before signing the informed consent form; those who have not used weight loss drugs or received weight loss treatments;jects with poor weight control after dietary and exercise interventions; 3.Those who are willing to sign the written informed consent form and comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1.The investigator deems that the subject has a disease state that may prevent the completion of the follow-up during the observation period. 2.The investigator determines that there are situations affecting the compliance of this study for the subject during the treatment with Efsubaglutide Alfa.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight;Waist circumference;Body fat composition; | — |
Countries
China
Contacts
Public ContactJia Weiping
600 Yishan Road, Xuhui District, Shanghai
Outcome results
None listed